Indacaterol
Indacaterol is a pharmaceutical drug with 40 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 36 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
10
Mid Stage
28
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
94.7%
36 of 38 finished
5.3%
2 ended early
0
trials recruiting
40
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD
Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
Drug Utilization Study for Olodaterol
Clinical Trials (40)
Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD
Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
Drug Utilization Study for Olodaterol
Ultra-long Acting Bronchodilator Therapy in Asthmatics
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
Efficacy of Indacaterol 150 µg Versus Formoterol
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol
Effect of Indacaterol on Inspiratory Capacity (IC)
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
Pulmonary Gas Exchange Response to Indacaterol in COPD
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 40